Metoaxiro (Metoprolol Tartrate)

Metoprolol Tartrate is indicated for cardiovascular conditions that involve elevated heart rate or blood pressure.

• Hypertension: lowers systemic blood pressure and reduces cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand to relieve chest pain.
• Post‑myocardial infarction: improves survival by reducing cardiac workload.
• Heart failure: enhances ventricular function and reduces hospitalizations.
• Cardiac arrhythmias: controls heart rate in supraventricular tachyarrhythmias.

• Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in cardiac tissue, diminishing sympathetic stimulation. This reduces heart rate, myocardial contractility, and cardiac output, leading to lower blood pressure and decreased myocardial oxygen consumption, which underlies its antihypertensive, anti‑anginal, antiarrhythmic, and heart‑failure benefits.

Metoprolol Tartrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Bradycardia (slow heart rate)
• Cold extremities
• Gastrointestinal upset (nausea, abdominal pain)
• Headache

Serious or Rare Side Effects

• Severe bradycardia or heart block
• Marked hypotension
• Bronchospasm, especially in patients with asthma
• Allergic reactions (rash, angioedema)
• Depression or mood changes
• Cardiogenic shock in rare cases

Before initiating therapy, clinicians should consider several safety measures.

• Monitor blood pressure: ensure adequate control without excessive hypotension.
• Assess heart rate: avoid use in patients with baseline bradycardia.
• Review respiratory history: caution in asthma or chronic obstructive pulmonary disease.
• Adjust for renal or hepatic impairment: dose may need modification.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metoprolol Tartrate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Combined use with other AV‑node blockers (e.g., verapamil, diltiazem) may cause severe bradycardia.
• Concomitant clonidine withdrawal can precipitate hypertensive crisis.
• Potent CYP2D6 inhibitors (e.g., quinidine, fluoxetine) increase metoprolol levels.
• Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.
• Epinephrine: reduced therapeutic response.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may blunt antihypertensive effect.
• Diuretics: additive blood‑pressure lowering.
• Other antihypertensives: monitor for excessive hypotension.
• Certain antidepressants (e.g., sertraline): may require dose adjustment.
• Anesthetic agents: may enhance cardiovascular depression.